Gnubiotics has developed a first-in-class Animal Milk Oligosaccharide AMObiome to respond to the increasing demand for natural break-through products for companion and production animal health. The manufacturing partner is Evonik. With the first commercial lots successfully manufactured by Evonik, GNUbiotics has initiated two clinical trials.
Evonik will manufacture Gnubiotics’ AMObiome, a critical missing nutritional component that restores natural symbiosis in pets and livestock animals with microbiota imbalance. “We are excited about the partnership with Evonik as it allows us to manufacture our novel AMO to the highest production standards as we begin commercialization” said Yemi Adesokan, CSO at GNUbiotics. “We are pleased to support GNUbiotics by applying our technical expertise and industrial capabilities to enable the scale up and commercialization of AMObiome.” said, Dr. Jean-Luc Herbeaux, SVP and General Manager of the Evonik business line Health Care.
Two clinical studies
AMObiome is a patented complex and diverse AMO containing over 30 oligosaccharide species that support the Development, Protection and Restoration of the microbiome of pets and production animals. Pre-clinical studies of AMObiome have shown the selective promotion of key commensal microbes such as Lactobacillus spp, Akkermansia spp, Bacteriodes spp and Megamonas while intelligently moderating potential pathogens such as E. coli and Salmonella.
With the first commercial lots successfully manufactured by Evonik, GNUbiotics has initiated two clinical trials with AMObiome in cats and dogs known as RESILIENT1 and MOTIVATE1 that are based on guidelines set by the Association of American Feed Control Officials (AAFCO). These trials plus those in partnerships involve up to 300 animals.
(Press release)
Please login or sign up to comment.
Commenting guidelines